SR 144528 is a selective peripheral cannabinoid (CB2) receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.1,2 SR 144528 antagonizes the inhibitory effects of CP 55,940 on forskolin-induced adenylyl cyclase activity in CHO cells expressing hCB2 (IC50 = 10 nM) but not in cells expressing hCB1 (IC50 > 10 µM).1 SR 144528 has been used to investigate the contribution of the CB2 receptor in the control of pain initiation as well as suppression of inflammation and immune activation.3,4,5,6
1
Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther284(2)644-650(1998).
2
Portier, M., Rinaldi-Carmona, M., Pecceu, F., et al. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther288(2)582-589(1999).
3
Barth, F., and Rinaldi-Carmona, M. The development of cannabinoid antagonists. Curr Med Chem6745-755(1999).
4
Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce?Nat Rev Drug Discov7438-455(2008).
5
Iwamura, H., Suzuki, H., Ueda, Y., et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selection ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther296(2)420-425(2001).
6
Wright, K.L., Duncan, M., and Sharkey, K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol153263-270(2008).
Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce?Nat Rev Drug Discov7438-455(2008).
Portier, M., Rinaldi-Carmona, M., Pecceu, F., et al. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther288(2)582-589(1999).
Iwamura, H., Suzuki, H., Ueda, Y., et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selection ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther296(2)420-425(2001).
Wright, K.L., Duncan, M., and Sharkey, K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol153263-270(2008).
Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther284(2)644-650(1998).
Barth, F., and Rinaldi-Carmona, M. The development of cannabinoid antagonists. Curr Med Chem6745-755(1999).